M Beat 25 Tablet ER contains Metoprolol Succinate 25 mg, a cardioselective beta-1 adrenergic receptor blocker used primarily in the management of hypertension, angina pectoris, and heart failure. By selectively blocking beta-1 receptors in the heart, Metoprolol reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and decreasing myocardial oxygen demand. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing and improved patient compliance. M Beat 25 is indicated for the treatment of essential hypertension, stable angina, and as part of the management regimen for chronic heart failure to reduce morbidity and mortality. It may also be employed for secondary prevention following myocardial infarction. The drug should be used with caution in patients with bradycardia, heart block, or severe peripheral arterial disease. Common adverse effects include fatigue, dizziness, and gastrointestinal disturbances. Abrupt discontinuation should be avoided to prevent exacerbation of angina or precipitating myocardial infarction. Dose adjustments may be necessary in patients with hepatic impairment. M Beat 25 Tablet ER should be prescribed under medical supervision with regular monitoring of blood pressure, heart rate, and clinical response to optimize therapeutic outcomes and minimize potential risks.